Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Amitkumar Mehta, Umar Farooq, Andy Chen, Joseph P. McGuirk, Thomas Ly, Lilly Wong, Sarah Cooley, Bahram Valamehr, Rebecca Elstrom, Yu-Waye Chu, Jae H. Park

Blood (2022) 140 (Supplement 1): 4577–4578.

https://doi.org/10.1182/blood-2022-167194

Published: 2022

Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour

Blood (2022) 140 (Supplement 1): 4586–4587.

https://doi.org/10.1182/blood-2022-166994

Published: 2022

Journal Articles

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Rina M Mbofung, Xingyue Zong, Erika Varady, Alan M Williams, Ken L Hayama, Yijia Pan, Sushil Devkota, Brian Groff, Miguel Meza, Thomas Dailey, Tom Lee, Lilly Wong, Sarah Cooley, Ryan Bjordahl, Jode P Goodridge, Bahram Valamehr

Blood (2022) 140 (Supplement 1): 7388–7389.

https://doi.org/10.1182/blood-2022-169817

Published: 2022

Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij

Blood (2022) 140 (Supplement 1): 10327–10328.

https://doi.org/10.1182/blood-2022-166728

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Blood (2021) 138 (Supplement 1): 407.

https://doi.org/10.1182/blood-2021-148654

Published: 2021

Journal Articles

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, MD PhD, Zuzan Cayci, MD, Dixie Lewis, RN,BA, Joseph E. Maakaron, MD, Murali Janakiram, MD, Andersen Bartz, Steven Payne, BS, Carol Wong, MPH, Sarah Cooley, MD, Bahram Valamehr, PhD, Yu-Waye Chu, MD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 8.

https://doi.org/10.1182/blood-2020-141606

Published: 2020

Journal Articles

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

Sarah A. Holstein, MD PhD, Sarah Cooley, MD, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Catherine R Balint, BSc, William Van Der Touw, Michele L. Donato, MD, Philip L. McCarthy, MD, Paul K. Wallace, MS, PhD, Xiaokui Zhang, PhD, Robert Hariri, MD PhD, Mohamad A. Hussein, MDMBBS, Ravi Vij, MBBS

Blood (2019) 134 (Supplement_1): 4451.

https://doi.org/10.1182/blood-2019-128467

Published: 2019

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

Shijia Zhang, MD PhD, Yucai Wang, MD, Yvonne Datta, MD, Veronika Bachanova, MD PhD, Sarah Cooley, MD

Blood (2018) 132 (Supplement 1): 3293.

https://doi.org/10.1182/blood-2018-99-113533

Published: 2018

Journal Articles

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Dan S Kaufman, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 730.

https://doi.org/10.1182/blood-2018-99-114893

Published: 2018

Journal Articles

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Blood (2018) 132 (Supplement 1): 71.

https://doi.org/10.1182/blood-2018-99-113564

Published: 2018

Journal Articles

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Michael R Verneris, MD, Tao Wang, PhD, Stephen R. Spellman, Jennifer A. Sees, MPH, Michael D. Haagenson, MS, Sarah Cooley, MD, Katharine C. Hsu, MD PhD, Katharina Fleischhauer, Katharina Fleischhauer, Dean Anthony Lee, MD PhD, Sophie Paczesny, MD PhD, Hemalatha G. Rangarajan, MD, Jeffrey S. Miller, MD, Stephanie J. Lee, MD MPH

Blood (2018) 132 (Supplement 1): 4647.

https://doi.org/10.1182/blood-2018-99-116428

Published: 2018

Journal Articles

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Blood (2018) 132 (Supplement 1): 195.

https://doi.org/10.1182/blood-2018-195

Published: 2018

Journal Articles

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

Emily Chiu, PhD, Frank Cichocki, PhD, Martin Felices, PhD, Sarah Cooley, MD, Helen Chu, PhD, Moyar Q. Ge, PhD, Ryan Bjordahl, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 729.

https://doi.org/10.1182/blood-2018-99-112202

Published: 2018

Journal Articles

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Blood (2018) 131 (23): 2515–2527.

https://doi.org/10.1182/blood-2017-12-823757

Published: 2018

Includes: Supplemental data

Journal Articles

Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation

Sarah Cooley, Peter Parham, Jeffrey S. Miller

Blood (2018) 131 (10): 1053–1062.

https://doi.org/10.1182/blood-2017-08-752170

Published: 2018

Journal Articles

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Sarah Cooley, MD, Fiona He, MD BS, BA, Veronika Bachanova, MD PhD, Greg M Vercellotti, MD FACP, Todd E. DeFor, MS, Julie Curtsinger, Paul Alexander Robertson, MD, Kevin C Conlon, MD, Thomas A Waldmann, MD, David H. McKenna, MD, Bruce Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2017) 130 (Supplement 1): 2649.

https://doi.org/10.1182/blood.V130.Suppl_1.2649.2649

Published: 2017

Journal Articles

Pre-Transplant Exhausted Marrow Infiltrating T Lymphocytes in MRD Negative Patients with Acute Leukemia Predict Early Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation

Robin Williams, MDMS, Sarah Cooley, MD, Peter M. Gordon, MDPhD, Veronika Bachanova, MD PhD, Daniel J. Weisdorf, MD, Bruce Blazar, MD, John E. Wagner, MD, Jeffrey S. Miller, MD, Michael R Verneris, MD

Blood (2017) 130 (Supplement 1): 1997.

https://doi.org/10.1182/blood.V130.Suppl_1.1997.1997

Published: 2017

Journal Articles

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Blood (2017) 130 (Supplement 1): 656.

https://doi.org/10.1182/blood.V130.Suppl_1.656.656

Published: 2017

NARROW

Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T-Cell Therapy for Patients with Relapsed/Refractory B-Cell Malignancies

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells

Initial Clinical Activity of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Results of a Phase I Study of Pnk-007, Allogeneic, Off the Shelf NK Cell, Post Autologous Transplant in Multiple Myeloma (NCT02955550)

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Bortezomib-Based Consolidation/Maintenance Therapy for Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials

iPSC-Derived NK Cells and Anti-PD-1 Antibody Synergize to Enhance T Cell Cytokine and Cytolytic Responses Against Multiple Tumors

Facilitating Resolution of Life-Threatening Acute Graft-Versus-Host Disease By Supplementation of Human Chorionic Gonadotropin and Epidermal Growth Factor (Pregnyl): A Phase I Study

Outcomes of Pediatric Patients with Acute Leukemia Following Adult Unrelated Donor Transplant: The Impact of Donor KIR Gene Content and KIR Ligand Matching

Efficient Scale-up and Pre-Clinical Evaluation of NKG2C+ Adaptive NK Cell Expansion for Therapy Against High-Risk AML/MDS

Induced Pluripotent Stem Cell-Derived NK Cells Genetically Modified to Express NKG2C/DAP12 Mediate Potent Function When Targeted through an NKG2C/IL-15/CD33 Tri-Specific Killer Engager (TriKE)

First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation

Strategies to activate NK cells to prevent relapse and induce remission following hematopoietic stem cell transplantation

Neurological Consequences of Cytokine Release Syndrome Following Subcutaneous Recombinant IL-15 and Haploidentical Donor Natural Killer Cell Therapy for Advanced Acute Myeloid Leukemia

Pre-Transplant Exhausted Marrow Infiltrating T Lymphocytes in MRD Negative Patients with Acute Leukemia Predict Early Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation

Clinical Translation of Pluripotent Cell-Derived Off-the-Shelf Natural Killer Cell Cancer Immunotherapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only